Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x-rays?

Radiation Oncology

Frederik Wenz²  Muhammad Afzal¹  Carsten Herskind²  Elena Blank²  Sven Clausen²  Frank Schneider²  Muhammad Hammad Aziz¹ 

[1] Department of Physics, The Islamia University of Bahawalpur, Bahawalpur, Pakistan;Department of Radiation Oncology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany

关键词: accelerated partial breast irradiation;    intraoperative radiotherapy;    breast cancer;    radiotherapy;    Secondary cancer induction;   

Others  :  1160924
DOI  :  10.1186/1748-717X-6-174

 received in 2011-08-05, accepted in 2011-12-16,  发布年份 2011

【 摘 要 】

Background

Radiation induced secondary cancers are a rare but severe late effect after breast conserving therapy. Intraoperative radiotherapy (IORT) is increasingly used during breast conserving surgery. The purpose of this analysis was to estimate secondary cancer risks after IORT compared to other modalities of breast radiotherapy (APBI - accelerated partial breast irradiation, EBRT - external beam radiotherapy).

Methods

Computer-tomography scans of an anthropomorphic phantom were acquired with an INTRABEAM IORT applicator (diameter 4 cm) in the outer quadrant of the breast and transferred via DICOM to the treatment planning system. Ipsilateral breast, contralateral breast, ipsilateral lung, contralateral lung, spine and heart were contoured. An INTRABEAM source (50 kV) was defined with the tip of the drift tube at the center of the spherical applicator. A dose of 20 Gy at 0 mm depth from the applicator surface was prescribed for IORT and 34 Gy (5 days × 2 × 3.4 Gy) at 10 mm depth for APBI. For EBRT a total dose of 50 Gy in 2 Gy fractions was planned using two tangential fields with wedges. The mean and maximal doses, DVHs and volumes receiving more than 0.1 Gy and 4 Gy of organs at risk (OAR) were calculated and compared. The life time risk for secondary cancers was estimated according to NCRP report 116.

Results

IORT delivered the lowest maximal doses to contralateral breast (< 0.3 Gy), ipsilateral (1.8 Gy) and contralateral lung (< 0.3 Gy), heart (1 Gy) and spine (< 0.3 Gy). In comparison, maximal doses for APBI were 2-5 times higher. EBRT delivered a maximal dose of 10.4 Gy to the contralateral breast and 53 Gy to the ipsilateral lung. OAR volumes receiving more than 4 Gy were 0% for IORT, < 2% for APBI and up to 10% for EBRT (ipsilateral lung). The estimated risk for secondary cancer in the respective OAR is considerably lower after IORT and/or APBI as compared to EBRT.

Conclusions

The calculations for maximal doses and volumes of OAR suggest that the risk of secondary cancer induction after IORT is lower than compared to APBI and EBRT.

【 授权许可】

   
2011 Aziz et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Elkin EB, Hudis C, Begg CB, Schrag D: The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer 2005, 104:1149-1157.
• [2]Anderson WF, Jatoi I, Devesa SS: Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943-2002). Breast Cancer Res Treat 2006, 99:333-340.
• [3]Peto R, Boreham J, Clarke M, Davies C, Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000, 355:1822.
• [4]Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-years survival: an overview of randomised trials. Lancet 2005, 366(9503):2087-106.
• [5]Bartelink H, Horiot JC, Poortmans P, Van den Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M, European Organization for Research and Treatment of Cancer Radiotherapy and Breast Cancer Groups: Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001, 345:1378-1387.
• [6]Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N: Twenty year followup of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347:1233-1241.
• [7]Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K: Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003, 160:381-407.
• [8]Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I, Tokuoka S: Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 2003, 160:707-717.
• [9]Xu XG, Bednarz B, Paganetti H: A review of dosimetry studies on external beam radiation treatment with respect to second cancer induction. Phys Med Biol 2008, 53:R193-241.
• [10]International Commission of Radiation Protection. Publication 60: 1990 recommendation of the ICRP Ann ICRP 1992, 21:1-3.
• [11]Arthur DW, Vicini FA: Accelerated partial breast irradiation as a part of breast conservation therapy. J Clin Oncol 2005, 23:1726-1735.
• [12]Wazer DE, Berle L, Graham R, Chung M, Rothschild J, Graves T, Cady B, Ulin K, Ruthazer R, Dipetrillo TA: Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys 2002, 53:889-897.
• [13]Pignol JP, Rakovitch E, Keller BM, Sankreacha R, Chartier C: Tolerance and acceptance results of palladium-103 permanent breast seed implant Phase I/II study. Int J Radiat Oncol Biol Phys 2009, 73:1482-1488.
• [14]Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M: Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010, 376:91-102.
• [15]Intra M, Gentilini O, Veronesi P, Ciocca M, Luini A, Lazzari R, Soteldo J, Farante G, Orecchia R, Veronesi U: A new option for early breast cancer patients previously irradiated for Hodgkin's diease: intraoperative radiotherapy with electrons (ELIOT). Breast Cancer Res 2005, 7(5):R828-832. BioMed Central Full Text
• [16]Vicini FA, Remouchamps V, Wallace M, Sharpe M, Fayad J, Tyburski L, Letts N, Kestin L, Edmundson G, Pettinga J, Goldstein NS, Wong J: Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early stage breast cancer treated with breast conserving therapy. Int J Radiat Oncol Biol Phys 2003, 57:1247-1253.
• [17]Wenz F, Welzel G, Blank E, Hermann B, Steil V, Sütterlin M, Kraus-Tiefenbacher U: Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-Rays: The first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys 2010, 77(5):1309-14.
• [18]Herskind C, Griebel J, Kraus-Tiefenbacher U, Wenz F: Sphere of equivalence--a novel target volume concept for intraoperative radiotherapy using low-energy × rays. Int J Radiat Oncol Biol Phys 2008, 72:1575-81.
• [19]Herskind C, Wenz F: Radiobiological comparison of hypofractionated accelerated partial-breast irradiation (APBI) and single-dose intraoperative radiotherapy (IORT) with 50-kV X-rays. Strahlenther Onkol 2010, 186(8):444-51.
• [20]National Council on Radiation Protection and Measurements (NCRP) report 116 [http://www.ncrponline.org/Publications/116press.html] webcite
• [21]Pignol JP, Keller BM, Ravi A: Doses to internal organs for various breast radiation techniques - implications on the risk of secondary cancers and cardiomyopathy. Radiat Oncol 2011, 6:5. BioMed Central Full Text
• [22]Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, Ron E: Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010, 102:220-26.
• [23]Hall EJ, Wuu CS: Radiation-induced second cancers: the impact of 3DCRTand IMRT. Int J Radiat Oncol Biol Phys 2003, 56:83-8.
• [24]Hall EJ: Intensity modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006, 65:1-7.
• [25]Little MP, Muirhead CR: Evidence for curvilinearity in the cancer incidence dose-response in the Japanese atomic bomb survivors. Int J Radiat Biol 1996, 70:83-94.
• [26]Le Pogam MA, Rubino C, Diallo I, et al.: Radiation dose fractionation and second cancer risks after breast cancer treatment. Rad Prot Dosimetry, in press.
• [27]de Vathaire F, Nucleon édition: Données épidémiologiques sur les effets cancérigènes des faibles doses de rayonnements Ionisants. Annexe 4. Relation dose-effet et l'estimation des effets cancérogènes des faibles doses de rayonnements ionisants. Rapport Conjoint n°2, Acad Sc et Acad Med (version Française).-Paris 2005, 147-168.
• [28]Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P: Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001, 51:679-90.
• [29]Obedian E, Fischer DB, Haffty BG: Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 2000, 18:2406-12.
• [30]Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A: Institut Curie Breast Cancer Study Group. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 2008, 98(5):870-4.
• [31]Zablotska LB, Neugut AI: Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 2003, 97:1404-11.
• [32]Inskip PD, Stovall M, Flannery JT: Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994, 86:983-988.
• [33]Lettmaier S, Kreppner S, Lotter M, Walser M, Ott OJ, Fietkau R, Strnad V: Radiation exposure of the heart, lung and skin by radiation therapy for breast cancer: a dosimetric comparison between partial breast irradiation using multicatheter brachytherapy and whole breast teletherapy. Radiother Oncol 2010, 100:189-94.
• [34]Brenner DJ, Leu CS, Beatty JF, Shefer RE: Clinical relative biological effectiveness of low-energy x-rays emitted by miniature x-ray devices. Phys Med Biol 1999, 44:323-33.
• [35]Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D: Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005, 23:4179-4191.
• [36]Burnell M, Levine MN, Chapman JA, Bramwel V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE: Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 2010, 28:77-82.
• [37]Cardwell CR, Abnet CC, Cantwell MM, Murray LJ: Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-63.
• [38]Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V: Oral bisphosphonates and risk of cancer of esophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
• [39]Brosius FC, Waller BF, Roberts WC: Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981, 70(3):519-530.
• [40]McGale P, Darby SC: Low doses of ionizing radiation and circulatory diseases: a systematic review of the published epidemiological evidence. Radiat Res 2005, 163(3):247-257.
• [41]Shimizu Y, Pierce DA, Preston DL, Mabuchi K: Studies of the mortality of atomic bomb survivors. Report 12, part II. Noncancer mortality: 1950-1990. Radiat Res 1999, 152(4):374-389.
• [42]Taylor CW, McGale P, Darby SC: Cardiac risks of breast-cancer radiotherapy: a contemporary view. Clin Oncol (R Coll Radiol) 2006, 18(3):236-246.
• [43]Rutqvist LE, Liedberg A, Hammar N, Dalberg K: Myocardial infarction among women with early- stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 1998, 40:359-363.
• [44]Nixon AJ, Manola J, Gelman R, Bornstein B, Abner A, Hetelekidis S, Recht A, Harris JR: No long-term increase in cardiac- related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 1998, 16:1374-1379.
• [45]Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA, Solin LJ: Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006, 24:4100-4106.
• [46]Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97(6):419-24.
• [47]Schultz-Hector S, Trott K: Radiation-induced cardiovascular diseases: Is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007, 67:10-8.
• [48]Lohr F, El-Haddad M, Dobler B, Grau R, Wertz HJ, Kraus-Tiefenbacher U, Steil V, Madyan YA, Wenz F: Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. Int J Radiat Oncol Biol Phys 2009, 74(1):73-80.
• [49]Coon AB, Dickler A, Kirk MC, Liao Y, Shah AP, Strauss JB, Chen S, Turian J, Griem KL: Tomotherapy and multifield intensity-modulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy. Int J Radiat Oncol Biol Phys 2010, 78(1):104-10.
• [50]Abo-Madyan Y, Polednik M, Rahn A, Schneider F, Dobler B, Wenz F, Lohr F: Improving dose homogeneity in large breasts by IMRT: efficacy and dosimetric accuracy of different techniques. Strahlenther Onkol 2008, 184(2):86-92.
• [51]Gagliardi G, Lax I, Rutqvist LE: Partial irradiation of the heart. Semin Radiat Oncol 2001, 11:224-233.
• [52]Gagliardi G, Lax I, Soderstrom S, Gyenes G, Rutqvist LE: Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol 1998, 46:63-71.
• [53]Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A: Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large scale, single-instiution review. Int J Radiat Oncol Biol Phys 2007, 68(2):359-63.
• [54]Roychoudhuri R, Evans H, Robinson D, Moller H: Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004, 91:868-72.
• [55]Prochazka M, Granath F, Ekbom A, Shields PG, Hall P: Lung cancer risks in women with previous breast cancer. Eur J Cancer 2002, 38:1520-25.